Evolving Companion Diagnostics: From Targeted Markers to Full-Stack Multi-Omic Partnerships
- Beyond the Biomarker: From reactive testing to platform-driven strategy
- Partnering from IND to Launch: Diagnostics as a strategic asset
- Unlocking RNA and proteomics for IO, ADCs, and emerging modalities